Two randomized Phase II trials of a plant-derived quadrivalent influenza vaccine candidate enrolled 750 adults across two age groups to assess safety,humoral response,and cell-mediated immunity.
\nICS assays by flow cytometry,delivered by CellCarta,showed the 30 µg dose produced the most consistent responses in both cohorts,directly informing the dose taken forward to Phase III.
","stat_1_value":"","stat_1_label":"","stat_2_value":"","stat_2_label":"","stat_3_value":"","stat_3_label":"","button_text":"Learn More","button_url":" https://pubmed.ncbi.nlm.nih.gov/31166987/"},{"image_url":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-9-scaled.jpg","image_alt":"LCMV HB-101 CMV vaccine phase I trial ICS ELISpot CellCarta CD8 T-cell","stamp":"Scientific Publication","title":"LCMV Vaccine Phase I Trial","description":"The first-in-human Phase I trial of HB-101,a replication-deficient Lymphocytic Choriomeningitis Virus (LCMV) vector-based vaccine against cytomegalovirus,evaluated safety and immunogenicity in 54 participants.
\nUsing ICS and ELISpot assays,developed by CellCarta,the trial characterized dose-dependent polyfunctional CD8 T-cell and neutralizing antibody responses,providing the data used to justify further clinical development.
","stat_1_value":"","stat_1_label":"","stat_2_value":"","stat_2_label":"","stat_3_value":"","stat_3_label":"","button_text":"Learn More","button_url":"https://pubmed.ncbi.nlm.nih.gov/32313928/"}]}#-supreme-cellcarta-differentiators-8-736{items-data:[{"text":"Cell-Mediated Immunity Expertise"},{"text":"Platform Agnostic Workflow"},{"text":"Global Lab Network"},{"text":"Validation for Any Endpoints"},{"text":"Close Collaboration with Sponsors"}];margin-bottom:0px}#-supreme-cellcarta-faq-11-736{items-data:[{"faq_question":"What infectious disease indications does CellCarta support?","faq_answer":"CellCarta supports a broad range of infectious disease indications,including COVID-19,HIV/AIDS,hepatitis B and C,influenza,tuberculosis,dengue fever,malaria,flu,and brucellosis. Our teams have developed and validated assays for both clinical trials and biomarker research programs across these areas. If your indication is not listed,you can contact us to discuss custom assay development options.
"},{"faq_question":"What immune monitoring assays do you offer for vaccine trials?","faq_answer":"Our vaccine support capabilities include ICS assays by flow cytometry to measure intracellular cytokine expression at the single-cell level,ELISpot and FluoroSpot assays for T-cell and B-cell cytokine secretion measurement,and MSD for multiplexed cytokine profiling. All assays can be customized to specific antigens and validated for exploratory,secondary,or primary clinical trial endpoints in turnaround times aligned with your trial timeline.
"},{"faq_question":"Can you develop custom assays for new or emerging pathogens?","faq_answer":"Yes. CellCarta has a demonstrated track record of rapidly developing and validating custom assays for novel pathogens. During the COVID-19 pandemic,our teams partnered with biopharma companies to quickly develop SARS-CoV-2-specific ICS,ELISpot and FluoroSpot assays for use in clinical trials. Our teams can adapt established assay formats to new antigens and validate them to meet primary or secondary endpoint requirements.
"},{"faq_question":"What sample types do you work with?","faq_answer":"CellCarta works with a broad range of sample types for infectious disease programs,including whole blood,fresh and cryopreserved PBMCs,serum,and plasma. Our teams can provide guidance on optimal sample stability and logistics management,including PBMC processing for high-quality samples. In-house sample procurement,preparation,stimulation,and stabilization services are also available where needed."}]}#-supreme-cellcarta-featured-resources-12-746{cards-data:[{"image_url":"https://cellcarta.com/wp-content/uploads/2024/11/Picture1.4-Border.jpg","image_alt":"","card_type":"Blog ","date":"Nov 19,2024","reading_time":"","title":"ELISpot vs. ICS:Optimizing Immune Monitoring in Clinical Trials with the Right Functional Assay","description":"","url":"/science-hub/elispot-vs-ics/","link_target":"_self"},{"image_url":"https://cellcarta.com/wp-content/uploads/2020/10/Image_Finale.jpg","image_alt":"","card_type":"Blog","date":"Oct 29,2020","reading_time":"","title":"ELISpot vs ICS Assays:Perfect Method in Immuno-Oncology Trials","description":"","url":"/science-hub/ics-and-elispot-for-the-study-of-cell-response-choosing-the-optimal-method-in-immuno-oncology-or-covid-19-vaccination-trials/","link_target":"_self"},{"image_url":"https://cellcarta.com/wp-content/uploads/2026/07/Cellcarta-Tagline_logo.jpg","image_alt":"","card_type":"Publication ","date":"Jan 18,2018 ","reading_time":"","title":"Humoral and Cell-Mediated Immune Responses to H5N1 Plant-Made Virus-Like Particle Vaccine Are Differentially Impacted by Alum and GLA-SE Adjuvants in a Phase 2 Clinical Trial ","description":"","url":"https://pubmed.ncbi.nlm.nih.gov/29387473/","link_target":"_blank"}]}#-supreme-cellcarta-indications-4-736{cards-data:[{"image":"https://cellcarta.com/wp-content/uploads/2026/07/COVID-19-148.jpg","image_alt":"Lyme disease therapeutic assay development clinical trials","title":"Lyme Disease","description":"Customized disease biomarker panels for Lyme disease research panels."},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/HIV-_-AIDS-63.jpg","image_alt":"HIV AIDS immune monitoring quantitative biomarker measurement","title":"HIV / AIDS","description":"Quantitative biomarker measurement and immune monitoring to support HIV/AIDS clinical trials."},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/Influenza-442.jpg","image_alt":"Influenza vaccine immunogenicity cellular humoral immune response","title":"Influenza","description":"Cellular and humoral immune response monitoring for influenza vaccine programs."},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/Viral-Hepatitis-465.jpg","image_alt":"Viral hepatitis B C biomarker development clinical testing","title":"Viral Hepatitis","description":"Biomarker development and clinical testing for hepatitis B and hepatitis C programs."},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/Global-Infectious-Diseases-575.jpg","image_alt":"Global infectious diseases tuberculosis dengue malaria brucellosis assay development","title":"Global Infectious Diseases","description":"Assay development for tuberculosis,dengue fever,malaria,brucellosis,and more."}]}#-supreme-cellcarta-overview-3-736{stats-data:[{"number":"25+","label":"Years of expertise"},{"number":"8","label":"Global labs"},{"number":"750+","label":"Employees"}]}#-supreme-cellcarta-tab-content-5-736{tabs-data:[{"tab_title":"Immune Profiling","content_title":"","content_body":"Characterize immune responses across clinical phases of infectious disease trials with our suite of complex immune monitoring capabilities,including:
\nAdvance your vaccine program with assays designed to characterize cellular and antibody-mediated immunity. Our teams can develop and validate assays built around your specific pathogen and trial timeline,including:
\nFor studies interested in MHC peptide analysis and characterizing how the immune system identifies non-self antigens,CellCarta can support these investigations using high-resolution mass spectrometry,HLA typing,and advanced bioinformatic tools.
\nOur workflow directly detects presented peptides with a high degree of clarity,supporting immune monitoring and infectious disease research applications.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-18-2-1-scaled.jpg","image_alt":""},{"tab_title":"Biomarker Development","content_title":"","content_body":"Generate validated,regulatory-ready biomarker data and perform quantitative measurements for clinical trials for a wide range of infectious diseases with our state-of-the-art mass spectrometry and flow cytometry platforms.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-45-scaled.jpg","image_alt":"Biomarker development mass spectrometry flow cytometry infectious disease"}]}#-supreme-cellcarta-technology-6-736{cards-data:[{"card_title":"Flow Cytometry","card_image":"https://cellcarta.com/wp-content/uploads/2026/06/Flow-Cytometry-Services-118.jpg","image_alt":"Flow cytometry high-parameter immune cell population monitoring","card_description":"Identify,quantify,and monitor immune cell populations with high-parameter flow cytometry panels,with expert guidance on panel design,data analysis,and reporting. With access to a wide range of leading flow cytometry platforms,including the spectral CYTEK Aurora platform,our workflows can support all sample types.
","card_link":"/platforms/flow-cytometry/","card_link_text":"Discover"},{"card_title":"FluoroSpot and ELISpot","card_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-7-scaled.jpg","image_alt":"FluoroSpot ELISpot antigen-specific T cell B cell response assays","card_description":"Detect cytokines and measure antigen-specific T- and B-cell responses with ELISpot and FluoroSpot assays customized to your specific antigen. Commercial assays and custom development is available,with validation specific to your study’s specifications.
","card_link":"/capabilities/immunoassay-services/fluorospot-elispot/","card_link_text":"Discover"},{"card_title":"Meso Scale Discovery (MSD)","card_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-28-2-scaled.jpg","image_alt":"MSD Meso Scale Discovery multiplex cytokine chemokine immunoassay","card_description":"Profile cytokines,chemokines,and inflammation markers from small sample volumes with the MSD platform,delivering high-throughput,multiplexed data from as little as 25 µL of serum or plasma. MSD’s low limit of detection and broad dynamic ranges make it a suitable platform for targeted protein quantification in infectious disease programs.
","card_link":"/capabilities/immunoassay-services/meso-scale-discovery/","card_link_text":"Discover"}]}